Pharma/Fine Chemicals Roundup – October 30
7:22 AM MDT | October 30, 2012 | By DEEPTI RAMESH
Lonza chairman denies takeover discussions
By Ian Young
Lonza chairman Rolf Soiron has denied speculation that the company has held acquisition talks with a potential buyer for Lonza. Soiron told Swiss newspaper SonntagsZeitung, in an interview published yesterday, that "there are and were no talks, not to mention negotiations." The speculation is "rumors" and "Lonza should maintain its independence," Soiron is quoted as saying. The speculation last month surrounded possible interest from Sabic or BASF in acquiring Lonza.
SAFC signs API development deal with Korean firm
Sigma-Aldrich Fine Chemicals (SAFC), the custom manufacturing and services business unit of Sigma-Aldrich, says it has signed an agreement with CrystalGenomics (Seoul) to support the development of active pharmaceutical ingredients (APIs) for next-generation non-steroidal anti-inflammatory drugs (NSAID). The agreement represents SAFC's first pre-formulation services contract into the growing Korean pharmaceutical market, the company says. CrystalGenomics, under the agreement, will employ SAFC's Pharmorphix pre-formulation technology services which are based at Cambridge, UK, to enable understandings of the physical properties of APIs. The services can also aid in determining the selection of optimal crystallization processes, ensure batch-to-batch consistency in manufacturing and help to maintain efficacy and patient safety, SAFC says.
DSM signs biologics development and manufacturing agreement with Australian firm
DSM Pharmaceutical Products (Parsippany, NJ), the business unit of DSM which provides contract manufacturing and development services to the pharma and biopharma industries, says it has signed a biologics contract manufacturing agreement with Paranta Biosciences (Melbourne). Financial terms were not disclosed. Paranta Biosciences is an early stage drug development company that develops and commercializes biotherapeutics based on recombinant human follistatin for the treatment of respiratory diseases. The contract covers the process development and manufacture by DSM of Paranta’s lead recombinant human protein. DSM will manufacture the product at the previously announced new Brisbane, Australia facility.
Shin-Etsu acquires stake in NanoCarrier
Shin-Etsu Chemical and NanoCarrier (Kashiwa, Japan) says that Shin-Etsu will acquire a majority stake in NanoCarrier. NanoCarrier is involved in the research and development (R&D) and production of pharmaceuticals using micellar nanoparticles technology. The board of directors of NanoCarrie, on 26 October, approved a plan to allot 12,000 ordinary shares to Shin-Etsu by way of a private placement for ¥689 million ($8.7 million). Shin-Etsu will invest another ¥360 million in NanoCarrier through the acquisition of an additional 12,000 NanoCarrier shares from Whiz Partners (Tokyo). The transactions will be completed by 15 November. NanoCarrie will use the proceeds for its R&D activities.
IMCD acquires food and pharma ingredients distributor in Indonesia
Distributor IMCD Group (Rotterdam) says it has signed an agreement to acquire Alam Subur Tirta Kencana (Jakarta), a leading food ingredients distributor in Indonesia. Financial details of the deal were not disclosed. Alam Subur is a leading distributor and supplier for food and beverage ingredients with offices and warehouses in Jakarta. It also supplies pharmaceutical and nutraceutical ingredients. IMCD, under the deal, will also acquire Alam Subur’s affiliate company Sapta Permata (Surabaya, Indonesia).
AMRI promotes Steven Hagen to senior v.p./pharmaceutical development and manufacturing
Albany Molecular Research Inc. (AMRI; Albany, NY) says that Steven R. Hagen, has been promoted to senior v.p. of pharmaceutical development and manufacturing. He will continue to report to AMRI chairman, president and CEO Thomas E. D’Ambra. Hagen is responsible for about two-thirds of AMRI’s contract operations, including chemical development, analytical and pharmaceutical quality services, small scale cGMP manufacturing of active ingredients and dosage forms, and large scale commercial manufacturing. These operations encompass facilities located in Albany, Rensselaer and Syracuse, NY; Burlington, MA; Holywell, UK; and Hyderabad and Aurangabad, India.
Firms invest further— despite tough environment
Most pharmaceutical fine chemical manufacturers interviewed by CW at CPhI, the largest annual trade fair for the global pharmaceutical ingredients industry, held recently in Madrid, said they were optimistic about the outlook for the sector and planning a range of investments to grow their businesses. Companies believe that the US FDA’s Generic Drug User Fee Act (GDUFA), which became effective on 1 October 2012, will help eliminate from the market manufacturers with unacceptably low levels of quality.